Heterologous Ad26.COV2.S Prime and mRNA-Based Boost COVID-19 Vaccination Regimens: The SWITCH Trial Protocol

Front Immunol. 2021 Sep 24;12:753319. doi: 10.3389/fimmu.2021.753319. eCollection 2021.
No abstract available

Keywords: Ad26.Cov2.S; BNT162.b2; COVID-19; Heterologous vaccine regimen; Homologous vaccination regimen; SARS-CoV-2; mRNA1273; randomized clinical trial.

Publication types

  • Clinical Trial Protocol

MeSH terms

  • 2019-nCoV Vaccine mRNA-1273
  • Ad26COVS1
  • BNT162 Vaccine
  • COVID-19 Vaccines / administration & dosage*
  • COVID-19* / immunology
  • COVID-19* / prevention & control
  • Humans
  • Immunization, Secondary

Substances

  • Ad26COVS1
  • COVID-19 Vaccines
  • 2019-nCoV Vaccine mRNA-1273
  • BNT162 Vaccine

Supplementary concepts

  • COVID-19 vaccine booster shot